Adults 45 to 85, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
National Annie Colonoscopy Survey ScorePrimary· Day 21 (Up to 7 Days Post-Procedure)
7-item assessment of participant satisfaction with the "Annie" text intervention. Items are rated on a 5-point scale from 1 (strongly disagree) to 5 (strongly agree). The total score is the sum of responses and ranges from 7 to 35; higher scores indicate greater satisfaction with the intervention.
Group
Value
95% CI
Text Message Intervention
29.56
± 4.16
Percentage of Participants Who Attend Scheduled Colonoscopy AppointmentSecondary· Up to Day 14
Assessed via patient's electronic health record.
Group
Value
95% CI
Text Message Intervention
96
No Intervention
92
Percentage of Participants Who Had Adequate Bowel Preparation at Colonoscopy AppointmentSecondary· Up to Day 14
Assessed via patient's electronic health record.
Group
Value
95% CI
Text Message Intervention
79
No Intervention
91
Sponsor's own description
Colorectal cancer is a common but preventable condition, and increasing colorectal cancer screening is one of the most impactful public health contributions in the field of gastroenterology. Text messaging is a simple, cheap, and rapid method to reach patients that may improve adherence to colonoscopy appointments as well as simplify the process of bowel preparation. The purpose of the study is to evaluate the feasibility of a pilot bidirectional text messaging intervention on attendance for screening/surveillance colonoscopy and bowel preparation quality at an urban VA hospital. The goal is to improve adherence to colonoscopy among patients who are due for a repeat colonoscopy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino
· Phase 3
· recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
· Phase 1, PHASE2
· recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
· Phase 1, PHASE2
· recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes
· recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes
· recruiting
Other NYU Langone Health trials
Trials by the same sponsor.
NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study
· NA
· not yet recruiting
NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease
· NA
· not yet recruiting
NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors
· NA
· not yet recruiting
NCT06236087 — Overdose Prevention Centers and Behavioral Health
· not yet recruiting
NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest
· Phase 1
· suspended
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
Last refreshed: 20 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06185374.